{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:13:56Z","timestamp":1788401636201,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100023448","name":"Robert Koch-Institut","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some individuals infected with severe acute respiratory syndrome coronavirus 2 experience long-term symptoms, termed post COVID-19 condition (PCC). Pandemic-era studies have demonstrated moderate effectiveness of COVID-19-vaccines in preventing PCC. However, as population immunity has evolved and variant-adapted vaccines have been introduced, estimates of vaccine effectiveness and disease frequency from the post-pandemic era are needed to guide policy-making and communication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated whether one mRNA COVID-19 vaccine dose during the 2023\/2024 season was associated with reduced PCC risk in the following six months among adults aged\u2009\u2265\u200960\u2009years in Germany. We conducted a retrospective cohort study using nationwide, outpatient claims data and performed descriptive and Poisson regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In our cohort of 19,121,674 patients, 3,437,701 (18.0%) received one dose of a seasonal COVID-19 vaccine and 36,830 fulfilled the PCC case definition (incidence: 0.2%). Vaccinated individuals were older (median age 75\u2009years) compared to those who were not vaccinated (71\u2009years), with a higher proportion being female (54% vs. 46% male). 0.08% of vaccinated patients were diagnosed with PCC during study follow-up, compared to 0.22% non-vaccinated. One vaccine dose was associated with lower risk (adjusted Risk Ratio 0.37; 95% CI 0.36\u20130.39) of receiving a PCC diagnosis at six months post-vaccination compared to no vaccination, translating to a vaccine effectiveness of 63%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results demonstrate a low PCC-incidence and a strong protective association between seasonal COVID-19 vaccination and PCC during the first post-pandemic season. These findings can help improve acceptance of COVID-19-vaccines and support doctors\u2019 and patients\u2019 decision-making regarding vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13803-8","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:35:19Z","timestamp":1781346919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of seasonal mRNA COVID-19 vaccination against post COVID-19 condition between July 2023 and September 2024 among adults aged\u2009\u2265\u200960\u2009years in Germany: a population-based cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Nita","family":"Perumal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Peine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Harder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"13803_CR1","doi-asserted-by":"publisher","first-page":"101472","DOI":"10.1016\/j.lanepe.2025.101472","volume":"59","author":"S de Bruijn","year":"2025","unstructured":"de Bruijn S, Huiberts AJ, Andeweg SP, Hoeve CE, Schipper M, Grobbee DE, de Melker HE, van de Wijgert JHHM, van den Hof S, Knol MJ, et al. Post-COVID-19 condition in individuals infected with SARS-CoV-2 in autumn 2023 in the Netherlands: a prospective cohort study with pre- and post-infection data. Lancet Reg Health Eur. 2025;59:101472. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101472.","journal-title":"LancetThe Lancet Reg Health - Eur"},{"key":"13803_CR2","unstructured":"UK Office for National Statistics. Statistical bulletin: prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK (30 March 2023). London: UK Office for National Statistics; 2023. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk\/30march2023#cite-this-statistical-bulletin."},{"key":"13803_CR3","unstructured":"World Health Organization. Fact sheet: post COVID-19 condition (long COVID). Geneva: World Health Organization; 2022. https:\/\/www.who.int\/europe\/news-room\/fact-sheets\/item\/post-covid-19-condition."},{"key":"13803_CR4","doi-asserted-by":"publisher","first-page":"127870","DOI":"10.1016\/j.vaccine.2025.127870","volume":"67","author":"N Abdul Aziz","year":"2025","unstructured":"Abdul Aziz N, Kirsebom FCM, Allen A, Andrews N. Effectiveness of spring 2024 (XBB.1.5) and autumn 2024 (JN.1) COVID-19 vaccination against hospitalisation in England. Vaccine. 2025;67:127870. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127870.","journal-title":"Vaccine"},{"key":"13803_CR5","unstructured":"St\u00e4ndige Impfkommission beim Robert Koch-Institut. Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut 2025. St\u00e4ndige Impfkommission beim Robert Koch-Institut; 2025. https:\/\/edoc.rki.de\/handle\/176904\/12372.5."},{"key":"13803_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/13589","volume":"50","author":"T Rieck","year":"2025","unstructured":"Rieck T, Steffen A, Lottes M, Badenschier F, Feig M, Rau C. Impfquoten in Deutschland. Epid Bull. 2025;50:3\u201313. https:\/\/doi.org\/10.25646\/13589.","journal-title":"Epid Bull"},{"issue":"12","key":"13803_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.cmi.2025.07.026","volume":"31","author":"C Peine","year":"2025","unstructured":"Peine C, Stoliaroff-Pepin A, Reinacher U, Heldt K, Sarganas G, Piechotta V, et al. Effectiveness of COVID-19 vaccines against post-COVID-19 condition\/long COVID: systematic review and meta-analysis. Clin Microbiol Infect. 2025;31(12):1961\u201371. https:\/\/doi.org\/10.1016\/j.cmi.2025.07.026.","journal-title":"Clin Microbiol Infect"},{"key":"13803_CR8","doi-asserted-by":"publisher","unstructured":"Hou Y, Gu T, Ni Z, Shi X, Ranney ML, Mukherjee B. Global prevalence of long COVID, its subtypes, and risk factors: an updated systematic review and meta-analysis. Open Forum Infect Dis. 2025;12(9):ofaf533. https:\/\/doi.org\/10.1093\/ofid\/ofaf533.","DOI":"10.1093\/ofid\/ofaf533"},{"key":"13803_CR9","doi-asserted-by":"publisher","unstructured":"Rieck T, Feig M, An der Heiden M, Siedler A, Wichmann O. Assessing varicella vaccine effectiveness and its influencing factors using health insurance claims data, Germany, 2006 to 2015. Eurosurveillance. 2017;22(17). https:\/\/doi.org\/10.2807\/1560-7917.ES.2017.22.17.30521.","DOI":"10.2807\/1560-7917.ES.2017.22.17.30521"},{"key":"13803_CR10","doi-asserted-by":"publisher","unstructured":"Relan P, Motaze NV, Kothari K, Askie L, Le Polain O, Van Kerkhove MD, et al. Severity and outcomes of omicron variant of SARS-CoV-2 compared to delta variant and severity of Omicron sublineages: a systematic review and metanalysis. BMJ Glob Health. 2023;8(7):e012328. https:\/\/doi.org\/10.1136\/bmjgh-2023-012328.","DOI":"10.1136\/bmjgh-2023-012328"},{"issue":"19","key":"13803_CR11","doi-asserted-by":"publisher","first-page":"12422","DOI":"10.3390\/ijerph191912422","volume":"19","author":"P Gao","year":"2022","unstructured":"Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(19):12422. https:\/\/doi.org\/10.3390\/ijerph191912422.","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"6","key":"13803_CR12","doi-asserted-by":"publisher","first-page":"106358","DOI":"10.1016\/j.jinf.2024.106358","volume":"89","author":"NKN Chow","year":"2024","unstructured":"Chow NKN, Tsang CYW, Chan YH, Telaga SA, Ng LYA, Chung CM, et al. The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis. J Infect. 2024;89(6):106358. https:\/\/doi.org\/10.1016\/j.jinf.2024.106358.","journal-title":"J Infect"},{"key":"13803_CR13","doi-asserted-by":"publisher","first-page":"105493","DOI":"10.1016\/j.ebiom.2024.105493","volume":"111","author":"Y Wang","year":"2025","unstructured":"Wang Y, Alcalde-Herraiz M, Guell KL, Chen L, Mateu L, Li C, et al. Refinement of post-COVID condition core symptoms, subtypes, determinants, and health impacts: a cohort study integrating real-world data and patient-reported outcomes. EBioMedicine. 2025;111:105493. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105493.","journal-title":"EBioMedicine"},{"issue":"6","key":"13803_CR14","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/ije\/dyw341","volume":"45","author":"J Textor","year":"2017","unstructured":"Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Ellison GTH. Robust causal inference using directed acyclic graphs: the R package \u2018dagitty\u2019. Int J Epidemiol. 2017;45(6):1887\u201394. https:\/\/doi.org\/10.1093\/ije\/dyw341.","journal-title":"Int J Epidemiol"},{"issue":"17\u201318","key":"13803_CR15","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.vaccine.2003.11.052","volume":"22","author":"H Kelly","year":"2004","unstructured":"Kelly H, Attia J, Andrews R, Heller RF. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine. 2004;22(17\u201318):2192\u201398. https:\/\/doi.org\/10.1016\/j.vaccine.2003.11.052.","journal-title":"Vaccine"},{"key":"13803_CR16","doi-asserted-by":"publisher","unstructured":"Lundberg-Morris L, Leach S, Xu Y, Martikainen J, Santosa A, Gisslen M, et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ. 2023;383:e076990. https:\/\/doi.org\/10.1136\/bmj-2023-076990.","DOI":"10.1136\/bmj-2023-076990"},{"issue":"9","key":"13803_CR17","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/infdis\/jiac136","volume":"226","author":"C Chen","year":"2022","unstructured":"Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226(9):1593\u2013607. https:\/\/doi.org\/10.1093\/infdis\/jiac136.","journal-title":"The J Infect Dis"},{"key":"13803_CR18","unstructured":"European Centre for Disease Prevention and Control. COVID-19 vaccination coverage in the EU\/EEA during the 2024\u201325 season campaigns, 1 August 2024 \u2013 28 March 2025. Stockholm: European Centre for Disease Prevention and Control; 2025. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/covid-19-vaccination-coverage-eueea-during-2024-25-season-campaigns."},{"key":"13803_CR19","unstructured":"Robert Koch Institute. VacMap - German vaccine coverage dashboard. Berlin: Robert Koch Institute; 2025. https:\/\/public.data.rki.de\/t\/public\/views\/VacMap\/StartdashboardNavigation?%3Aembed=y%26%3Atabs=n."},{"key":"13803_CR20","doi-asserted-by":"publisher","unstructured":"Carazo S, Phimmasone J, Skowronski DM, Giguere K, Ouakki M, Talbot D, et al. Effectiveness of COVID-19 vaccination and prior infections to reduce long COVID risk during the pre-omicron and omicron periods. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf549.","DOI":"10.1093\/cid\/ciaf549"},{"issue":"10","key":"13803_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41577-023-00904-7","volume":"23","author":"DM Altmann","year":"2023","unstructured":"Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618\u201334. https:\/\/doi.org\/10.1038\/s41577-023-00904-7.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"13803_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1473-3099(25)00476-1","volume":"26","author":"B Zhang","year":"2026","unstructured":"Zhang B, Wu Q, Jhaveri R, Zhou T, Becich MJ, Bisyuk Y, et al. Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study. Lancet Infect Dis. 2026;26(2):127\u201338. https:\/\/doi.org\/10.1016\/S1473-3099(25)00476-1.","journal-title":"The Lancet Infect Dis"},{"issue":"4","key":"13803_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jinf.2022.01.012","volume":"84","author":"AA Mensah","year":"2022","unstructured":"Mensah AA, Lacy J, Stowe J, Seghezzo G, Sachdeva R, Simmons R, et al. Disease severity during SARS-COV-2 reinfection: a nationwide study. J Infect. 2022;84(4):542\u201350. https:\/\/doi.org\/10.1016\/j.jinf.2022.01.012.","journal-title":"J Infect"},{"issue":"1","key":"13803_CR24","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-024-44973-1","volume":"15","author":"J Wei","year":"2024","unstructured":"Wei J, Stoesser N, Matthews PC, Khera T, Gethings O, Diamond I, et al. Risk of SARS-CoV-2 reinfection during multiple omicron variant waves in the UK general population. Nat Commun. 2024;15(1):1008. https:\/\/doi.org\/10.1038\/s41467-024-44973-1.","journal-title":"Nat Commun"},{"issue":"11","key":"13803_CR25","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/vaccines10111777","volume":"10","author":"J Romate","year":"2022","unstructured":"Romate J, Rajkumar E, Gopi A, Abraham J, Rages J, Lakshmi R, et al. What contributes to COVID-19 vaccine hesitancy? A systematic review of the psychological factors associated with COVID-19 vaccine hesitancy. Vaccines (Basel). 2022;10(11):1777. https:\/\/doi.org\/10.3390\/vaccines10111777.","journal-title":"Vaccines (Basel)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13803-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13803-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13803-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T16:02:26Z","timestamp":1781366546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13803-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13803"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13803-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was deemed not necessary; therefore, this study was not submitted to an Ethics Review Board. All data were collected as part of routine surveillance under public health law (German Infection Protection Act) and anonymized prior to transmission to the Robert Koch Institute. The authors did not have access to identifiable individual data. Similarly, the need for consent to participate was deemed unnecessary under the German Infection Protection Act and because the data were anonymized.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was deemed not necessary. All data were collected as part of routine surveillance under public health law (German Infection Protection Act) and anonymized prior to transmission to the Robert Koch Institute. The authors did not have access to identifiable individual data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1140"}}